PMID- 32506311
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 40
IP  - 1
DP  - 2021 Jan
TI  - Clinical effectiveness of iguratimod based on real-world data of patients with 
      rheumatoid arthritis.
PG  - 123-132
LID - 10.1007/s10067-020-05208-y [doi]
AB  - OBJECTIVES: Iguratimod (IGU) is a conventional synthetic disease-modifying drug 
      that has been approved based on its additive effects with methotrexate (MTX) for 
      the treatment of rheumatoid arthritis (RA). The objective of the study is to 
      establish the effectiveness of IGU with versus IGU without MTX irrespective of 
      whether MTX is well tolerated or not by the patients. METHODS: Disease activity 
      scores in 177 RA patients treated using IGU were retrospectively evaluated at 
      baseline and after 4, 12, and 24 weeks, and adverse events (AEs) were noted. 
      RESULTS: IGU reduced the disease activity parameters, disease activity score 
      (DAS)-ESR, DAS-CRP, the simplified disease activity index (SDAI), and clinical 
      disease activity index (CDAI) in the concomitant MTX and non-MTX, female and 
      male, and young and elderly patient groups after 24 weeks. Multivariate analysis 
      demonstrated that IGU was more effective with concomitant MTX and in elderly and 
      male patients. Severe AEs were observed only in the elderly group: two cases of 
      pneumonia, 1 of pneumocystis pneumonia, 1 of heart failure, and 1 of salivary 
      gland adenoma. CONCLUSIONS: IGU is effective for RA, especially with concomitant 
      MTX, and in elderly and male patients. Key Points * Iguratimod is effective for 
      RA, especially with concomitant MTX, and in elderly and male patients. * Since 
      all serious adverse events were in the elderly group in this study, sufficient 
      monitoring for adverse events, especially for elderly RA patients, is needed 
      during iguratimod therapy.
FAU - Mizutani, Satoshi
AU  - Mizutani S
AUID- ORCID: 0000-0002-4321-5357
AD  - Division of Rheumatology, Department of Internal Medicine, School of Medicine, 
      Fujita Health University, Toyoake, 470-1192, Aichi, Japan. 
      satoshi.mizutani@med.toho-u.ac.jp.
AD  - Department of Internal Medicine, Yokkaichi Hazu Medical Center, Yokkaichi, 
      510-0016, Mie, Japan. satoshi.mizutani@med.toho-u.ac.jp.
AD  - Division of Rheumatology, Department of Internal Medicine, Toho University School 
      of Medicine, Ota-ku, 143-8541, Tokyo, Japan. satoshi.mizutani@med.toho-u.ac.jp.
FAU - Kodera, Hitoshi
AU  - Kodera H
AD  - Department of Internal Medicine, Yokkaichi Hazu Medical Center, Yokkaichi, 
      510-0016, Mie, Japan.
FAU - Sato, Yoshiko
AU  - Sato Y
AD  - Department of Internal Medicine, Yokkaichi Hazu Medical Center, Yokkaichi, 
      510-0016, Mie, Japan.
FAU - Nanki, Toshihiro
AU  - Nanki T
AUID- ORCID: 0000-0002-3482-074X
AD  - Division of Rheumatology, Department of Internal Medicine, Toho University School 
      of Medicine, Ota-ku, 143-8541, Tokyo, Japan.
FAU - Yoshida, Shunji
AU  - Yoshida S
AUID- ORCID: 0000-0002-4040-1963
AD  - Division of Rheumatology, Department of Internal Medicine, School of Medicine, 
      Fujita Health University, Toyoake, 470-1192, Aichi, Japan.
FAU - Yasuoka, Hidekata
AU  - Yasuoka H
AUID- ORCID: 0000-0002-2405-6282
AD  - Division of Rheumatology, Department of Internal Medicine, School of Medicine, 
      Fujita Health University, Toyoake, 470-1192, Aichi, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200606
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Chromones)
RN  - 0 (Sulfonamides)
RN  - 4IHY34Y2NV (iguratimod)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Aged
MH  - *Antirheumatic Agents/therapeutic use
MH  - *Arthritis, Rheumatoid/drug therapy
MH  - Chromones
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Methotrexate/therapeutic use
MH  - Retrospective Studies
MH  - Sulfonamides
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Elderly patients
OT  - Iguratimod
OT  - Methotrexate
OT  - Rheumatoid arthritis
EDAT- 2020/06/09 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/06/08 06:00
PHST- 2020/02/13 00:00 [received]
PHST- 2020/05/28 00:00 [accepted]
PHST- 2020/05/26 00:00 [revised]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/06/08 06:00 [entrez]
AID - 10.1007/s10067-020-05208-y [pii]
AID - 10.1007/s10067-020-05208-y [doi]
PST - ppublish
SO  - Clin Rheumatol. 2021 Jan;40(1):123-132. doi: 10.1007/s10067-020-05208-y. Epub 
      2020 Jun 6.